secwatch / observer

8-K filed November 1, 2024, 7:59 PM ET ticker CNSP CIK 0001729427

regulatory confidence high sentiment negative materiality 0.75

Nasdaq panel grants CNS Pharmaceuticals temporary exception until March 11, 2025 to meet bid price rule

CNS Pharmaceuticals, Inc.

Company received Nasdaq deficiency notice on Sept 12, 2024 for bid price below $1.00 for 30 consecutive days.
Not eligible for standard 180-day compliance period due to cumulative reverse stock splits of 250:1 or more in prior two years.
After hearing, Nasdaq panel granted exception until March 11, 2025 to regain compliance.
Panel reserves right to reconsider; Listing Council may review within 45 days.

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001683168-24-007533
form_type: 8-K
ticker: CNSP
cik: 0001729427
company_name: CNS Pharmaceuticals, Inc.
filed_at: 2024-11-01T23:59:59+00:00
discovered_at: 2026-05-14T18:03:09.386631+00:00
generated_at: 2026-05-30T06:59:36.750828+00:00
sec_items: ["8.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001683168-24-007533
json_url: https://secwatch.observer/filing/0001683168-24-007533.json
markdown_url: https://secwatch.observer/filing/0001683168-24-007533.md
text_url: https://secwatch.observer/filing/0001683168-24-007533.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824007533/0001683168-24-007533-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824007533/cns_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

LESL

Leslie's regains Nasdaq compliance for minimum market value of publicly held shares

Leslie's, Inc. June 1, 2026, 4:28 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

OTLK

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days

Outlook Therapeutics, Inc. June 1, 2026, 9:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

VYGR

FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's

Voyager Therapeutics, Inc. June 1, 2026, 8:00 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

EXFY

Expensify regains Nasdaq minimum bid price compliance

Expensify, Inc. May 29, 2026, 5:15 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SLXN

Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted

Silexion Therapeutics Corp May 29, 2026, 7:00 AM ET regulatory Items 3.03, 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing

RICHTECH ROBOTICS INC. May 28, 2026, 4:49 PM ET regulatory Items 3.01, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

MNKD

FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29

MANNKIND CORP May 28, 2026, 8:37 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SNAL

Snail receives Nasdaq extension to Sept 22, 2026 to regain listing compliance

Snail, Inc. May 27, 2026, 4:25 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001683168-24-007533

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.